Author

admin

Browsing

It only took the first game of Week 1 to deliver the first upset of the 2025 college football season.

South Florida quarterback Byrum Brown shined and the defense dominated Boise State to soundly defeat the No. 25 Broncos 34-7 in Tampa on Thursday, Aug. 28.

Despite the loss of Heisman Trophy runner-up Ashton Jeanty, Boise State entered the season as the Group of Five’s top College Football Playoff contender after making appearance in the 12-team field last season. The Broncos were the only Group of Five team ranked in the preseason US LBM Coaches Poll. It looked like Boise State could continue the momentum after taking a 7-0 lead in the first quarter.

But it was all Bulls after that.

South Florida scored 34 unanswered points, including a fake punt in the third quarter that resulted in a touchdown and extended the lead to double digits. Boise State’s offense was out of sorts, with two fumbles in the first half stopping any momentum. Playing desperate in the second half, the Broncos couldn’t convert fourth down attempts that resulted in South Florida touchdowns. The game was well wrapped up in the fourth quarter.

Brown was the star of the day, completing 16-of-24 passes for 210 yards while running for two touchdowns and 43 yards on 14 carries.

The loss of Jeanty clearly hurt the Broncos. Last season, they were eighth in the country in rushing yards per game at 240.4. Against South Florida, the Broncos finished with 122 rushing yards, while quarterback Maddux Madsen struggled completing passes with a 25-for-46 mark with 225 passing yards.

It’s the first ranked win for South Florida since 2016, which snapped a 19-game losing streak against ranked opponents.

What USF win, Boise State loss means

The race to represent the Group of Five in the playoff is wide open, and a new contender has been added.

Boise State’s chances of a repeat appearance drastically drop with the blowout loss and it will surely be out of the coaches poll by Week 2. It makes it a tougher hill to climb back into playoff consideration since the only loss it suffered in the regular season in 2024 was a three point loss to Oregon.

Now the Broncos will likely need a perfect rest of the season, which will be tough given they play at Notre Dame to start October. They also play another Group of Five contender in UNLV.

With the Group of Five spot seemingly open, South Florida enters the conversation as coach Alex Golesh continues to turn things around in Tampa; the Bulls are coming off back-to-back 7-6 seasons with bowl wins after they went 1-11 in in 2022 before hiring Golesh.

Even with a statement win to start the season, South Florida still has a daunting starting schedule. It will play at Florida in Week 2 and then host Miami the following week for three straight games against ranked opponents to start the season. A road trip to Memphis is also on the schedule.

However, another upset win could really catapult the Bulls into playoff consideration.

This post appeared first on USA TODAY

Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on through generations. So what is genetics investing?

When it comes to genetics investing, companies in this niche of the life science sector are mostly focused on four submarkets: DNA sequencing, genetic testing, gene therapy and genomics, which includes gene editing.

This life sciences submarket has gained much attention from investors over the past several years. It has provided a launching pad for a number of biotech firms developing and commercializing novel treatments and drugs addressing a wide range of diseases with unmet needs.

For those looking to dive into the genetics sector, there are numerous investment opportunities to consider. Investing in gene stocks is the most common route, but there are risks due to the market’s volatility, especially when it comes to wins or losses with the US Food and Drug Administration (FDA).

Exchange-traded funds (ETFs) are another popular option for gaining exposure to the industry, and come with less risk than investing in a single stock.

In this article

    What are the key areas of the genetics sector?

    Before diving into investment opportunities in the genetics market, it’s important to understand the industry and the key areas of genetics mentioned above.

      What investors should know about the genetics market

      In the biotech sector, gene therapy is one of the more advanced treatment options, and gene therapy pipeline candidates are robust in late-stage clinical trials.

      In terms of what will — and already has — disrupted the genetics industry, CRISPR gene-editing technology has been on the rise for quite some time. It uses short repeating DNA sequences with “spacers” dividing them to treat genetic diseases.

      While the use of the technology is still in its early stages, in the coming years it’s expected to have a big impact on how genetic diseases are treated, and there are a range of clinical trials underway involving CRISPR technology. So far, the only FDA approved CRISPR-based medicine is Casgevy, developed by Vertex Pharmaceuticals (NASDAQ:VRTX) and CRISPR Therapeutics (NASDAQ:CRSP). It was originally approved in late 2023 for the treatment of sickle cell disease.

      The prominence of gene therapies in the life science sector was a major theme at the 2025 JPMorgan Healthcare Conference in January 2025. Peter Marks, then-director of the FDA’s Center for Biological Evaluation and Research, told attendees that his agency is aiming to accelerate approvals for gene therapies.

      In 2024, the FDA expanded approvals for CRISPR-based Casgevy to beta-thalassemia, and it also approved Pfizer’s (NYSE:PFE) Beqvez and PTC Therapeutics’ (NASDAQ:PTC) Kebilidi.

      Despite experiencing a challenging year in 2024, there is still a lot of optimism in the gene therapy sector. Also speaking at the January conference, Alliance for Regenerative Medicine president Tim Hunt said he believes 10 new cell and gene therapy treatments could reach blockbuster status by 2030.

      “No one’s saying there aren’t headwinds, but we are seeing important signs of growth,” he added.

      Looking at DNA sequencing, this market is driven by advances in biotech, the increasing prevalence of cancer and rising demand for precision medicine, as well as higher investment in research and development. DNA sequencing has become a vital component of this growth and has played a key role in remodeling molecular biology and genomics research.

      Genetic testing is another segment of the genetics industry that is growing at a fast pace. Unsurprisingly, technological breakthroughs have had a huge impact on genetic testing, and so has the fact that governments and regulatory bodies are turning their attention to this market in order to regulate and raise awareness to treat diseases such as cancer, cystic fibrosis and sickle cell anemia.

      Biotech and pharmaceutical companies are also expressing interest in this sector, which is expected to further fuel genetics sector growth in the coming years. Mergers and acquisitions activity is also expected to increase as companies seek to expand their product portfolios new candidates and technologies.

      As can be seen, the genetics industry is vast and complex, but is also ripe with investment opportunities.

      How to invest in gene stocks

      Investors looking to invest in the field of genetics through stocks have many options, from large-cap biotech companies to pure-play gene therapy, gene editing and genetic testing stocks.

      See the list below for genetics companies to consider, and check out the linked stock lists for more options.

      Large-cap gene stocks

      There are a number of large-cap biotech companies that have significant focuses on the field of genomics. Here are a few to consider:

      Amgen (NASDAQ:AMGN)
      A global leader in biotech, Amgen uses advanced human genetics to develop and manufacture therapeutics targeting a variety of diseases with unmet medical needs. The company’s subsidiary deCODE Genetics is researching how human genetic diversity influences disease.

      AbbVie (NYSE:ABBV)
      Research-based global biopharmaceutical company AbbVie that addresses several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology. AbbVie is collaborating with ADARx Pharmaceuticals to develop siRNA therapeutics, viewed as a promising genetic medicine approach for silencing disease-causing genes.

      Regeneron Pharmaceuticals (NASDAQ:REGN)
      Regeneron Pharmaceuticals creates medicines for a wide variety of diseases. The Regeneron Genetics Center is conducting one of the world’s largest genetics sequencing efforts in collaboration with health organizations around the world.

      Gene editing (CRISPR) stocks

      There are a variety of options for investors looking to buy in on the field of gene editing stocks, including:

      CRISPR Therapeutics (NASDAQ:CRSP)
      CRISPR Therapeutics and its partner Vertex Pharmaceuticals co-developed drug Casgevy, a CRISPR/Cas9 genome-edited cell therapy. Casgevy is the first ever treatment based on CRISPR technology to be approved for the US market, as well as by the European Medicines Agency and Health Canada.

      Intellia Therapeutics (NASDAQ:NTLA)
      Intellia Therapeutics is a gene editing biotech company developing drugs for patients with genetic and autoimmune diseases. The company’s drug pipeline includes late-stage clinical programs for therapies targeting hereditary angioedema and transthyretin amyloidosis.

      Vertex Pharmaceuticals (NASDAQ:VRTX)
      Vertex Pharmaceuticals is the other half of the team behind Casgevy. It also offers exposure to other sectors of genomics, with approved treatments for cystic fibrosis and a pipeline of genetic and cell therapies. Its investigational VX-880 islet cell replacement therapy could restore insulin production in patients with type 1 diabetes.

      Gene therapy stocks

      Gene therapy stocks and stem cell stocks are also popular choices for genetics investing. Here are a few to get you started:

      Novartis (NYSE:NVS)
      Switzerland-based Novartis is focused on treatments for a wide range of diseases, including cancers, malaria, leprosy and sickle cell disease. Novartis is developing adeno-associated-virus (AAV)-based and CRISPR-based gene therapies. Its Kymriah treatment was the first CAR-T cell therapy to be approved by the FDA, and the agency also approved its AAV-based therapy Zolgensma.

      Gilead Sciences (NASDAQ:GILD)
      Global biopharmaceutical company Gilead Sciences is advancing breakthrough medicines to prevent and treat serious diseases such as HIV, viral hepatitis and cancer. Its cell-based gene medicine for blood cancer, the CAR T-cell therapy Yescarta, was the second gene therapy approved by FDA.

      uniQure (NASDAQ:QURE)
      Genomic medicine company uniQure develops and markets gene therapy products for patients with severe genetic diseases. The company’s AAV-based gene therapy platform targets liver-directed and central nervous system disorders.

      Genetic testing stocks

      For those interested in genetic testing stocks, these three stocks provide a snapshot on different ways to get exposure to the sector:

      Exact Sciences (NASDAQ:EXAS)
      Exact Sciences focuses on molecular diagnostic tests. The company has developed a molecular screening technology platform called Cologuard that detects a range of cancers, including breast cancer and colorectal cancer.

      Fulgent Genetics (NASDAQ:FLGT)
      A leader in clinical diagnostic genetic sequencing, Fulgent Genetics is a full-service genomics testing company. Its proprietary technology platform, Picture Genetics, allows for the identification of personal DNA health markers in individual patients.

      Illumina (NASDAQ:ILMN)
      Illumina develops, manufactures and markets life science tools and integrated systems that enable the implementation of genomic solutions for the healthcare sector. Its focus is on oncology testing, genetic disease testing, reproductive health and research.

      How to invest in genomics ETFs

      For those who would prefer to invest in the genetics industry overall rather than buying shares in an individual gene stock, investing in genomics ETFs is the way to go. Here are some available ETFs that offer exposure to companies in the biotech and genetics sectors to start you off:

      ARK Genomic Revolution ETF (ARCA:ARKG)
      This ETF tracks firms focused on CRISPR technology, targeted therapeutics, bioinformatics, molecular diagnostics, stem cells and agricultural biology. Its holdings include CRISPR Therapeutics and Guardant Health (NASDAQ:GH).

      Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)
      The Global X Genomics & Biotechnology ETF invests in stocks that are involved in genomic science, which includes gene computational genomics and biotechnology. Its holdings include Illumina and Avidity Biosciences (NASDAQ:RNA).

      iShares Genomics Immunology and Healthcare ETF (ARCA:IDNA)
      The iShares Genomics Immunology and Healthcare ETF focuses on companies involved with genomics, immunology and bioengineering. Its holdings include Regeneron Pharmaceuticals and Arcellx (NASDAQ:ACLX).

      Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

      This post appeared first on investingnews.com

      Flowers, succulents and Formula One race cars helped fuel a 12% revenue bump for Lego during the first half of the year.

      The company reported a record 34.6 billion Danish kroner, or $5.4 billion, in revenue as part of its biannual earnings report on Wednesday. Operating profit rose 10% year over year to 9 billion Danish kroner, or $1.4 billion, the company said.

      “It’s the best first half ever,” Lego CEO Niels Christiansen told CNBC. “It’s a record on revenue, a record on operating profit, it’s a record on net profit. … So, we are very happy.”

      The brick maker launched 314 new sets during the first six months of the year, another record high. Lego has steadily added new product to its portfolio, branching out into home decor with wall art sets. It has also added new license partners and released sets tied to animated children’s program “Bluey” and fan-favorite anime “One Piece.”

      Up next is a multiyear partnership with Pokemon, due to hit shelves in 2026.

      “You can always find something that you really like, the pop culture you’re into or the passion point you have,” Christiansen said. “That works really well.”

      In expanding its catalog of product, Lego has also grown its consumer base. Gateways into the brand such as its line of botanicals — plants, flower bouquets and succulents — and its ongoing partnership with Epic Games — which brings Lego to the digital space and elements from the popular video game Fortnite into the physical world — have encouraged newcomers into the brick-building space, Christiansen said.

      “Then they figure out what it is and what it does for them, how it kind of allows them to express themselves, but also de-stress and focus on stuff in a different way,” he said. “So botanicals sets turn out to be good at recruiting new consumers into the brand, and then as soon as they build their botanical set, they may move on to building something else.”

      Lego opened 24 new stores globally during the first six months of the year. The company has been opening more physical retail locations in areas that, unlike the U.K. and the U.S., did not grow up with the iconic colored bricks. This includes countries such as China and India.

      Having brick-and-mortar places where kids and adults can get their hands on Legos and see the available sets has previously helped bolster sales.

      This post appeared first on NBC NEWS

      Google has eliminated more than one-third of its managers overseeing small teams, an executive told employees last week, as the company continues its focus on efficiencies across the organization.

      “Right now, we have 35% fewer managers, with fewer direct reports” than at this time a year ago, said Brian Welle, vice president of people analytics and performance, according to audio of an all-hands meeting reviewed by CNBC. “So a lot of fast progress there.”

      At the meeting, employees asked Welle and other executives about job security, “internal barriers” and Google’s culture after several recent rounds of layoffs, buyouts and reorganizations.

      Welle said the idea is to reduce bureaucracy and run the company more efficiently.

      “When we look across our entire leadership population, that’s mangers, directors and VPs, we want them to be a smaller percentage of our overall workforce over time,” he said.

      The 35% reduction refers to the number of managers who oversee fewer than three people, according to a person familiar with the matter. Many of those managers stayed with the company as individual contributors, said the person, who asked not to be named because the details are private.

      Google CEO Sundar Pichai weighed in at the meeting, reiterating the need for the company “to be more efficient as we scale up so we don’t solve everything with headcount.”

      Google eliminated about 6% of its workforce in 2023, and has implemented cuts in various divisions since then. Alphabet finance chief Anat Ashkenazi, who joined the company last year, said in October that she would push cost cuts “a little further.” Google has offered buyouts to employees since January, and the company has slowed hiring, asking employees to do more with less.

      Regarding the buyouts, executives at the town hall said that a total of 10 product areas have presented “Voluntary Exit Program” offers. They’ve applied to U.S.-based employees in search, marketing, hardware and people operations teams this year.

      Fiona Cicconi, Google’s chief people officer, said at last week’s meeting that between 3% and 5% of employees on those teams have accepted the buyouts.

      “This has been actually quite successful,” she said, adding “I think we can continue it.”

      Pichai said the company executed the voluntary buyouts after listening to employees, who said they preferred that route to blanket layoffs.

      “It’s a lot of work that’s gone into implementing the VEP program, and I’m glad we’ve done it,” Pichai said. “It gives people agency, and I’m glad to see it’s worked out well.”

      Cicconi said one of the main reasons employees are taking the buyouts is because they want to take time off from work.

      “It’s actually quite interesting to see who’s taking a VEP, and it’s people sort of wanting a career break, sometimes to take care of family members,” she said.

      CNBC previously reported that the layoffs hurt morale as the company was downsizing while at the same time issuing blowout earnings and seeing its stock price jump. Alphabet’s shares are up 10% this year after climbing 36% in 2024 and 58% the year prior.

      At another point in the town hall, employees asked if Google would consider a policy similar to Meta’s “recharge,” a month-long sabbatical that employees earn after five years at the company.

      “We have a lot of leaves, not least our vacation, which is there for exactly that — resting and recharging,” said Alexandra Maddison, Google’s senior director of benefits.

      She said the company is not going to offer paid sabbatical.

      “We’re very confident that our current offering is competitive,” Maddison said.

      Meta didn’t immediately respond to a request for comment.

      Other executives jumped in to compare the two companies’ benefits.

      “I don’t think they have a VEP at Meta by the way,” Cicconi said.

      Pichai then asked, to some laughs from the audience, “Should we incorporate all policies of Meta while we’re at it? Or should we only pick and choose the few policies we like?”

      “Maybe I should try running the company with all of Meta’s policies,” he continued. “No, probably not.”

      This post appeared first on NBC NEWS

      The Trump administration’s latest allegations of mortgage fraud have raised questions about a long-standing housing issue known as owner-occupancy mortgage fraud. But that type of fraud can be difficult to prove, experts say.

      President Donald Trump announced in a Truth Social post on Monday night that he was removing Federal Reserve governor Lisa Cook. He cited allegations made by Federal Housing Finance Agency Director Bill Pulte that Cook committed mortgage fraud by claiming homes in two different states as her primary residence at the same time.

      Cook’s attorney on Tuesday said Cook will file a lawsuit to challenge her removal.

      “President Trump has no authority to remove Federal Reserve Governor Lisa Cook,” the lawyer, Abbe Lowell, said in a statement.

      The Justice Department has also recently targeted Sen. Adam Schiff, D-Calif., and New York Attorney General Letitia James with similar mortgage fraud allegations.

      Here are the key things to know about owner-occupancy mortgage fraud, according to experts.

      The main reason a borrower could be motivated to claim a primary residence on a mortgage application is to get a lower interest rate for that home.

      Typically, mortgages for a primary residence have lower interest rates and homeowner’s insurance costs, said Keith Gumbinger, vice president of mortgage website HSH.

      Mortgage interest rates are generally 0.5% to 1% higher for investment properties than for primary homes, according to Bankrate. Homeowners also typically pay about 25% more for insurance as a landlord compared with a standard homeowners policy, according to the Insurance Information Institute.

      Owner-occupied means “you’re going to live there the majority of the time,” Gumbinger said. But there are limited exceptions, including for military service, parents providing housing for a disabled adult child or children providing housing for parents, according to Fannie Mae.

      If a homeowner changes primary residences, they need to inform their mortgage lender that the original property is no longer owner-occupied, Gumbinger said.

      There are also federal and state tax benefits for primary residences, according to Albert Campo, a certified public accountant and president of Campo Financial Group in Manalapan, New Jersey.

      For example, when an owner sells a home and makes a profit, they can take a capital gains exemption worth up to $250,000 for single filers or $500,000 for married couples filing jointly, as long as they meet certain IRS rules, including owner occupancy for two of the past five years.

      For tax purposes, a homeowner can have only one primary residence at a time.

      When a taxpayer owns more than one home, proving which one is the primary residence is “always based on facts and circumstances,” Campo said. For example, a primary residence is typically where an owner spends most of their time, votes, files their tax returns and receives mail, he said.

      A 2023 report from the Federal Reserve Bank of Philadelphia found that more than 22,000 “fraudulent borrowers” misrepresented their owner-occupancy status, out of 584,499 loans originated from 2005 to 2017. The data was based on a subsample from more than 15 million loans originated during this period.

      Typically, the fraudulent borrowers took out larger loans and had higher mortgage default rates, the authors found.

      However, this type of fraud may be “difficult to detect until long after the mortgage has been originated,” the authors wrote.

      “There is a difference between the court of law and the court of public opinion,” Jonathan Kanter, a law professor at Washington University in St. Louis and a former assistant attorney general, told CNBC’s “Squawk Box” last week when asked about Cook. “In the court of law, this is small ball and very difficult to prove.”

      “You’d have to establish not only that she filled out the form incorrectly, but she had the specific intent to deceive, to defraud banks, as opposed to just making a mistake,” he said.

      During fiscal year 2024, 38 mortgage fraud offenders were sentenced in the federal system, according to the United States Sentencing Commission’s interactive data analyzer. That number is up slightly from 34 offenders in 2023, but down from 426 offenders in 2015, the earliest date in that tool’s dataset. The U.S. Sentencing Commission data does not break out the types of mortgage fraud.

      This post appeared first on NBC NEWS

      The Trump administration’s latest allegations of mortgage fraud have raised questions about a long-standing housing issue known as owner-occupancy mortgage fraud. But that type of fraud can be difficult to prove, experts say.

      President Donald Trump announced in a Truth Social post on Monday night that he was removing Federal Reserve Governor Lisa Cook. He cited allegations made by Federal Housing Finance Agency Director Bill Pulte that Cook committed mortgage fraud by claiming homes in two different states as her primary residence at the same time.

      Cook’s attorney on Tuesday said Cook will file a lawsuit to challenge her removal.

      “President Trump has no authority to remove Federal Reserve Governor Lisa Cook,” the lawyer, Abbe Lowell, said in a statement.

      The Department of Justice has also recently targeted Sen. Adam Schiff, D-Calif., and New York Attorney General Letitia James with similar mortgage fraud allegations.

      Here are the key things to know about owner-occupancy mortgage fraud, according to experts.

      The main reason a borrower could be motivated to claim a primary residence on a mortgage application is to get a lower interest rate for that home.

      Typically, mortgages for a primary residence have lower interest rates and homeowner’s insurance costs, said Keith Gumbinger, vice president of mortgage website HSH.

      Mortgage interest rates are generally 0.5% to 1% higher for investment properties than for primary homes, according to Bankrate. Homeowners also typically pay about 25% more for insurance as a landlord compared with a standard homeowners policy, according to the Insurance Information Institute.

      Owner-occupied means “you’re going to live there the majority of the time,” Gumbinger said. But there are limited exceptions, including for military service, parents providing housing for a disabled adult child or children providing housing for parents, according to Fannie Mae.

      If a homeowner changes primary residences, they need to inform their mortgage lender that the original property is no longer owner-occupied, Gumbinger said.

      There are also federal and state tax benefits for primary residences, according to Albert Campo, a certified public accountant and president of Campo Financial Group in Manalapan, New Jersey.

      For example, when an owner sells a home and makes a profit, they can take a capital gains exemption worth up to $250,000 for single filers or $500,000 for married couples filing jointly, as long as they meet certain IRS rules, including owner occupancy for two of the past five years.

      For tax purposes, a homeowner can have only one primary residence at a time.

      When a taxpayer owns more than one home, proving which one is the primary residence is “always based on facts and circumstances,” Campo said. For example, a primary residence is typically where an owner spends most of their time, votes, files their tax returns and receives mail, he said.

      A 2023 report from the Federal Reserve Bank of Philadelphia found that more than 22,000 “fraudulent borrowers” misrepresented their owner-occupancy status, out of 584,499 loans originated from 2005 to 2017. The data was based on a subsample from more than 15 million loans originated during this period.

      Typically, the fraudulent borrowers took out larger loans and had higher mortgage default rates, the authors found.

      However, this type of fraud may be “difficult to detect until long after the mortgage has been originated,” the authors wrote.

      “There is a difference between the court of law and the court of public opinion,” Jonathan Kanter, a law professor at Washington University in St. Louis and a former assistant attorney general, told CNBC’s “Squawk Box” last week when asked about Cook. “In the court of law, this is small ball and very difficult to prove.”

      “You’d have to establish not only that she filled out the form incorrectly, but she had the specific intent to deceive, to defraud banks, as opposed to just making a mistake,” he said.

      During fiscal year 2024, 38 mortgage fraud offenders were sentenced in the federal system, according to the United States Sentencing Commission’s interactive data analyzer. That number is up slightly from 34 offenders in 2023, but down from 426 offenders in 2015, the earliest date in that tool’s dataset. The U.S. Sentencing Commission data does not break out the types of mortgage fraud.

      This post appeared first on NBC NEWS